LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Elucidation of the anti-β-cell dedifferentiation mechanism of a modified Da Chaihu Decoction by an integrative approach of network pharmacology and experimental verification.

    Chen, Hongdong / Guo, Jing / Cai, Yuzi / Zhang, Chao / Wei, Fudong / Sun, Hao / Cheng, Cheng / Liu, Weijing / He, Zhongchen

    Journal of ethnopharmacology

    2023  Volume 321, Page(s) 117481

    Abstract: Ethnopharmacological relevance: Modified Da Chaihu decoction (MDCH) is a traditional Chinese herbal prescription that has been used in the clinic to treat type 2 diabetes (T2D). Previous studies have confirmed that MDCH improves glycemic and lipid ... ...

    Abstract Ethnopharmacological relevance: Modified Da Chaihu decoction (MDCH) is a traditional Chinese herbal prescription that has been used in the clinic to treat type 2 diabetes (T2D). Previous studies have confirmed that MDCH improves glycemic and lipid metabolism, enhances pancreatic function, and alleviates insulin resistance in patients with T2D and diabetic rats. Evidence has demonstrated that MDCH protects pancreatic β cells via regulating the gene expression of sirtuin 1 (SIRT1) and forkhead box protein O1 (FOXO1). However, the detailed mechanism remains unclear.
    Aim of the study: Dedifferentiation of pancreatic β cells mediated by FOXO1 has been recognized as the main pathogenesis of T2D. This study aims to investigate the therapeutic effects of MDCH on T2D in vitro and in vivo to elucidate the potential molecular mechanisms.
    Materials and methods: To predict the key targets of MDCH in treating T2D, network pharmacology methods were used. A T2D model was induced in diet-induced obese (DIO) C57BL/6 mice with a single intraperitoneal injection of streptozotocin. Glucose metabolism indicators (oral glucose tolerance test, insulin tolerance test), lipid metabolism indicators (total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol), inflammatory factors (C-reactive protein, interleukin 6, tumor necrosis factor alpha), oxidative stress indicators (total antioxidant capacity, superoxide dismutase, malondialdehyde), and hematoxylin and eosin staining were analyzed to evaluate the therapeutic effect of MDCH on T2D. Immunofluorescence staining and quantification of FOXO1, pancreatic and duodenal homeobox 1 (PDX1), NK6 homeobox 1 (NKX6.1), octamer-binding protein 4 (OCT4), neurogenin 3 (Ngn3), insulin, and SIRT1, and Western blot analysis of insulin, SIRT1, and FOXO1 were performed to investigate the mechanism by which MDCH inhibited pancreatic β-cell dedifferentiation.
    Results: The chemical ingredients identified in MDCH were predicted to be important for signaling pathways related to lipid metabolism and insulin resistance, including lipids in atherosclerosis, the advanced glycation end product receptor of the advanced glycation end product signaling pathway, and the FOXO signaling pathway. Experimental studies showed that MDCH improved glucose and lipid metabolism in T2D mice, alleviated inflammation and oxidative stress damage, and reduced pancreatic pathological damage. Furthermore, MDCH upregulated the expression levels of SIRT1, FOXO1, PDX1, and NKX6.1, while downregulating the expression levels of OCT4 and Ngn3, which indicated that MDCH inhibited pancreatic dedifferentiation of β cells.
    Conclusions: MDCH has therapeutic effects on T2D, through regulating the SIRT1/FOXO1 signaling pathway to inhibit pancreatic β-cell dedifferentiation, which has not been reported previously.
    MeSH term(s) Humans ; Rats ; Mice ; Animals ; Insulin-Secreting Cells ; Diabetes Mellitus, Type 2/metabolism ; Insulin Resistance ; Diabetes Mellitus, Experimental/metabolism ; Cell Dedifferentiation ; Sirtuin 1/metabolism ; Network Pharmacology ; Mice, Inbred C57BL ; Insulin/metabolism ; Cholesterol/metabolism
    Chemical Substances Sirtuin 1 (EC 3.5.1.-) ; Insulin ; Cholesterol (97C5T2UQ7J)
    Language English
    Publishing date 2023-11-23
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 134511-4
    ISSN 1872-7573 ; 0378-8741
    ISSN (online) 1872-7573
    ISSN 0378-8741
    DOI 10.1016/j.jep.2023.117481
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy.

    Yu, Borui / Zhou, Mengqi / Dong, Zhaocheng / Zheng, Huijuan / Zhao, Yuxue / Zhou, Jingwei / Zhang, Chao / Wei, Fudong / Yu, Guoyong / Liu, Wei Jing / Liu, Hongfang / Wang, Yaoxian

    Pharmaceutical biology

    2023  Volume 61, Issue 1, Page(s) 1222–1233

    Abstract: Context: Diabetic nephropathy (DN) is the main cause of end-stage renal disease. Modified Shen-Yan-Fang-Shuai formula (M-SYFSF) has excellent clinical efficacy in treating diabetic kidney disease. However, the potential mechanism of M-SYFSF remains ... ...

    Abstract Context: Diabetic nephropathy (DN) is the main cause of end-stage renal disease. Modified Shen-Yan-Fang-Shuai formula (M-SYFSF) has excellent clinical efficacy in treating diabetic kidney disease. However, the potential mechanism of M-SYFSF remains unknown.
    Objective: To investigate the mechanism of M-SYFSF against DN by network pharmacological analysis and biological experiments.
    Materials and methods: Utilizing a web-based pharmacology database, the potential mechanisms of M-SYFSF against DN were identified.
    Results: Network pharmacological analysis showed that MAPK pathway was the potential pathway. Results showed that compared with the Model group, M-SYFSF significantly reduced 24h urine albumin, UACR, and serum creatinine levels (54.90 ± 26.67 vs. 111.78 ± 4.28, 8.87 ± 1.69 vs. 53.94 ± 16.01, 11.56 ± 1.70 vs. 118.70 ± 49.57, respectively), and improved renal pathological changes. Furthermore, the intervention of M-SYFSF reduced the expression of pro-inflammatory cytokines and inhibited the activation of MAPK pathway in AGEs-treated HK-2 cells.
    Discussion and conclusion: M-SYFSF is likely to reduce inflammation in DN by inhibiting the MAPK pathway. It provides a theoretical basis for the clinical application of M-SYFSF in the treatment of DN.
    MeSH term(s) Rats ; Male ; Humans ; Animals ; Diabetic Nephropathies/metabolism ; Network Pharmacology ; Rats, Sprague-Dawley ; Diabetes Mellitus, Experimental/complications ; Diabetes Mellitus, Experimental/drug therapy ; Diabetes Mellitus, Experimental/metabolism ; Drugs, Chinese Herbal/pharmacology ; Drugs, Chinese Herbal/therapeutic use ; Glycation End Products, Advanced/metabolism
    Chemical Substances Drugs, Chinese Herbal ; Glycation End Products, Advanced
    Language English
    Publishing date 2023-08-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 1440131-9
    ISSN 1744-5116 ; 1388-0209
    ISSN (online) 1744-5116
    ISSN 1388-0209
    DOI 10.1080/13880209.2023.2241521
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top